Cidara Therapeutics Inc. (CDTX) has announced a reduction in its workforce by approximately 30% to concentrate on advancing the clinical development of CD388, the company's innovative DFC candidate targeting influenza A and B.
The strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B.
The company continues business development discussions for its oncology drug-Fc conjugate (DFC) programs, including CBO421, a CD73 inhibitor, which recently received IND-clearance to commence a Phase 1 study.
CDTX closed Thursday's regular trading at $11.35 down $0.27 or 2.32%. In the after-hours trading, the stock further dropped $0.49 or 4.35%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.